A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma

Cancer Prevention Research

Volumn 6, Issue 2, 2013, Pages 74-81

  Puntoni, Matteo ^a   Branchi, Daniela ^a   Argusti, Alessandra ^a   Zanardi, Silvia ^a   Crosta, Cristiano ^c   Meroni, Emanuele ^d   Munizzi, Francesco ^b   Michetti, Paolo ^a   Coccia, Gianni ^a   De Roberto, Giuseppe ^c   Bandelloni, Roberto ^a   Turbino, Laura ^a   Minetti, Egle ^a   Mori, Marco ^a   Salvi, Sandra ^b   Boccardo, Simona ^b   Gatteschi, Beatrice ^b   Benelli, Roberto ^b   Sonzogni, Angelica ^c   De Censi, Andrea ^a  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BETA CATENIN; DNA NUCLEOTIDYLEXOTRANSFERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER RISK; CHEMOPROPHYLAXIS; COLON BIOPSY; COLON CANCER; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FAMILY HISTORY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PATIENT COMPLIANCE; POLYPECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SMOKING HABIT;

ADENOMA; ADENOMATOUS POLYPS; AGED; ALLOPURINOL; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PREOPERATIVE CARE; PREOPERATIVE PERIOD;

EID: 84874506154     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0249     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, HongWK, Fabian CJ, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
3. Sillars-Hardebol AH, Carvalho B, van Engeland M, Fijneman RJ, Meijer GA. Theadenoma hunt in colorectal cancer screening: defining the target. J Pathol 2012;226:1-6.
4. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 2006;12:3661-97.
5. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010;14:1-206.
6. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807-16.
7. Keshavarzian A, Zapeda D, List T, Mobarhan S. High levels of reactive oxygen metabolites in colon cancer tissue: analysis by chemiluminescence probe. Nutr Cancer 1992;17:243-9.
8. Haklar G, Sayin-Ozveri E, Yuksel M, Aktan AO, Yalcin AS. Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors. Cancer Lett 2001;165:219-24.
9. Rakieh C, Conaghan PG. Diagnosis and treatment of gout in primary care. Practitioner 2011;255:17-20, 2-3.
10. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58:87-114.
11. Samra ZQ, Pervaiz S, Shaheen S, Dar N, Athar MA. Determination of oxygenderived free radicals producer (xanthine oxidase) and scavenger (paraoxonase1)enzymes and lipid parameters in different cancer patients. Clin Lab 2011;57:741-7.
12. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 2002;33:774-97.
13. Reiners JJ, Thai G, Rupp T, Cantu AR. Assessment of the antioxidant/ prooxidant status of murine skin following topical treatment with 12-Otetradecanoylphorbol- 13-acetate and throughout the ontogeny of skin cancer. Part I. quantitation of superoxide dismutase, catalase, glutathione peroxidase and xanthine oxidase. Carcinogenesis 1991;12:2337-43.
14. Pence BC, Reiners JJ. Murine epidermal xanthine oxidase activity: correlation with degree of hyperplasia induced by tumour promoters. Cancer Res 1987;47:6388-6392.
15. Tanaka T. Cancer chemoprevention by natural products. Oncol Rep 1994;1:1139-55.
16. Mori H, Tanaka T, Sugie S, Yoshimi N. Chemopreventive effects of plant derived phenolic, organosulfur and other compounds on carcinogenesis in digestive organs. Environ Mutat Res Commun 1995;17:127-33.
17. Tanaka T, Kojima T, Kawamori T, Mori H. Chemoprevention of digestive organs carcinogenesis by natural product protocatechuic acid. Cancer 1995;75(Suppl.):1433-39.
18. Wei H, Bowen R, Cai Q, Barnes S, Wang Y. Antioxidant and antipromotional effects of the soybean isoflavonegenistein. Proc Soc Exp Biol Med 1995;208:124-30.
19. Klaunig JE. Chemopreventive effects of green tea components on hepatic carcinogenesis. Prev Med 1992;21:510-19.
20. Kono H, Rusyn I, Bradford BU, Connor HD, Mason RP, Thurman RG. Allopurinol prevents early alcohol-induced liver injury in rats. J Pharmacol Exp Ther 2000;293:296-303.
21. Gomez-Cabrera MC, Borras C, Pallardo FV, Sastre J, Ji LL, Vina J. Decreasing xanthine oxidase-mediated oxidative stress prevents useful cellular adaptations to exercise in rats.J Physiol 2005;567(Pt 1):113-20.
22. Rennert G, Almog R, Bonner JD, Rennert HS, Low M, Gruber SB. Allopurinol Use and Colorectal Cancer Risk. Abstract #C88 AACR Third Annual International Conference on Frontiers in Cancer Prevention Research, 2004, Seattle (WA), USA
23. Salim AS. Scavengers of oxygen-derived free radicals prolong survival in advanced colonic cancer. A new approach. Tumour Biol 1993;14:9-17.
24. Salim AS. Oxygen-derived free-radical scavengers prolong survival in colonic cancer. Chemotherapy 1992;38:127-34.
25. Kamiyama H, Suzuki K, Maeda T, Koizumi K, Miyaki Y, Okada S, et al. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene. 2012 Feb 6. [Epub ahead of print].
26. Nakajima T, Enomoto S, Ushijima T. DNA methylation: a marker for carcinogenexposure and cancer risk. Environ Health Prev Med 2008;13:8-15.
27. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007;40:142-50.
28. Grady WM. Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 2005;33(Pt 4):684-8.
29. Hajage D, de Rycke Y, Bollet M, Savignoni A, Caly M, PiergaJY, et al. External validation of adjuvant! Online breast cancerprognosis tool. Prioritising recommendations for improvement. PLoS ONE 2011;6: e27446.
30. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009;101:114-9.
31. Thu YM, Richmond A. NF-kB inducing kinase: a key regulator in the immunesystem and in cancer. Cytokine Growth Factor Rev 2010;21:213-26.
32. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/b-catenin signaling in gastrointestinal cancers. Gastroenterology 2012;142:219-32.
33. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, Izumi H, et al. Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer 1999;83:732-7.
34. Berney CR, Downing SR, Yang JL, Russell PJ, Crowe PJ. Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer. J Pathol 2000;191:15-20.
35. Frommer D. Cleansing ability and tolerance of three bowel preparations for colonoscopy. Dis Colon Rectum 1997;40:100-4.
36. National Cancer Institute. Common terminology criteria for adverse events; 2003 [Version 3.0, revised 2003 Jun 10]. Available from: http:// ctep.cancer.gov.
37. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-64.
38. Bromley M, Rew D, Becciolini A, Balzi M, Chadwick C, Hewitt D, et al. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa. Eur J Histochem 1996;40:89-100.
39. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241-6.
40. Clement MV, Stamenkovic I. Superoxide anion is a natural inhibitor of FAS-mediated cell death. Eur Mol Biol Org J 1996;15:216-25.
41. Chung CC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000;119:854-65.
42. Korineck V, Barker N, Morin PJ, Van Wichen D, De Weger R, Kinzler KW. Constitutive transcriptional activation by b catenin-Tef complex in APC-/- colon carcinoma. Science 1997;275:1784-7.
43. Morin PJ, Sparks AB, Krinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of b-catenin-Tcf signaling in colon cancer by mutations in b-catenin or APC. Science 1997;275:1787-90.
44. Tetsu O, McCormick F. b-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
45. Perkins ND. The diverse and complex roles of NF-kB subunits in cancer. Nat Rev Cancer 2012;12:121-32.
46. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90.
47. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 2001;10:961-6.
48. Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, et al. Lapatinib activity in premalignant lesions and HER-2- positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res 2011;4:1181-9.